Tremelimumab - AstraZeneca
Alternative Names: Anti CTLA 4 monoclonal antibody - AstraZeneca; CP-675; CP-675,206; IMJUDO; TicilimumabLatest Information Update: 18 Jul 2024
At a glance
- Originator Pfizer
- Developer Amgen; AstraZeneca; Cancer Research Institute; Dana-Farber Cancer Institute; Immunocore; MedImmune; Pfizer; University of Alabama at Birmingham
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Liver cancer; Non-small cell lung cancer
- Phase III Bladder cancer; Head and neck cancer; Malignant-mesothelioma; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Urogenital cancer
- Phase II Biliary cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Germ cell cancer; Glioblastoma; HER2 negative breast cancer; Lung cancer; Neuroendocrine tumours; Oesophageal cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Thyroid cancer
- Phase I/II Haematological malignancies; Malignant melanoma
- No development reported Diffuse large B cell lymphoma; Gynaecological cancer; Myelodysplastic syndromes; Vulvovaginal cancer
Most Recent Events
- 31 May 2024 Efficacy data from the phase Ib/II INEOV trial in Ovarian cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 31 May 2024 Efficacy and adverse events data from a phase III ADRIATIC trial in Small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology, 2024 (ASCO-2024)
- 01 May 2024 University of Alabama at Birmingham terminates a I/II trial for Cholangiocarcinoma (Combination therapy) in USA (IV) due to slow accrual and study sponsor decision (NCT04989218)